IndieBio

Since 2017, ZORA has been a leader in Israel’s impact space as an early-stage deep tech investor based in Tel Aviv. We are: Pragmatists who see partnership between innovators and corporates as the fastest path to a cleaner and healthier future; Seekers of rare opportunities for game-changing global impact; Hands-on investors and operators who work intimately with our teams as they bring innovations from lab to field; Voracious learners who derive endless energy from the world-class scientists and teams we have the honor to back. Our community of changemakers extends to our investors who put their capital to work in pursuit of a brighter tomorrow. Vision & mission Israel’s deeptech ecosystem offers unparalleled R&D capable ofaddressing our planet’s largest challenge - managing climate change while ensuring a sustainable food supply for a growing population. Leveraging this research into deployable products for the world’s largest economic actors - global corporations - presents opportunity to effect meaningful change at unprecedented scale. We partner with Israel’s leading scientists and technologists to convert lab-scale innovations into mainstream food, agriculture and climate solutions that transform the way global business is done -- healthfully, sustainably and resource-efficiently. Leadership ZORA was founded by Vanessa Bartram in 2017. Vanessa is an impact entrepreneur turned impact investor. She began her career in investment banking in Mexico City, advising middle-market companies on M&A and restructuring. She later founded the Miami-based impact HR company WorkSquare, which she grew to over $25M in revenue. Vanessa holds an MBA from Harvard, a BA from Princeton, and is a Heritage Fellow with the Wexner Foundation.

We partner early with unstoppable entrepreneurs leveraging breakthrough science and technology to pursue progress at scale. Everything we do revolves around a single problem: What are the best ways to reconcile economic growth with human and planetary health? We invest in teams and solutions that address multi-decade problems that humanity has no choice but to solve. Our focusing questionsHow can we decouple improving living standards from resource depletion? How can we ensure food, energy and materials supply security when confronted by deglobalization, multipolarity and the distractions of the attention economy? How can we improve life on Earth and unlock future economic growth potential by leveraging next-generation computing and exploring outer space? How can the clean industrialization of biological processes reduce humanity’s impact on our planet? How we invest in unstoppable founders We look to problems and unmet needs first and then to which technologies and solutions have the potential to address those problems effectively. We don’t push any one type of technology or limit ourselves to one field. We look for founders and companies at the pre-seed and seed stages leveraging the three basic disciplines (physics, chemistry, biology) to engineer economically viable solutions. We look for teams that are uniquely suited to address the opportunity and its inherent challenges and for solutions that are radically better, technically viable, and defensible. Some of the areas we are keen to continue exploring include clean commodities, space technology, industrial decarbonization, electro- and green chemistry, next-generation computing, new materials & production methods. How we partner for the long-term Starlight is a Pre-Seed and Seed investor and ideally the first institutional check into your company. Having been in your shoes as founders and scientists ourselves, we will serve as an ally in the journey ahead. Here’s what you can expect from working with us: We will lead or co-lead your first institutional round. We reserve capital for follow-on investment in later rounds, and we have to ability to partner with our LPs to augment our participation in future opportunities. We will be personally invested in your success, as a large portion of our fund comes from our own team. We will put a particular focus on ensuring that your roadmap is focused on the key risks and milestones unique to addressing the most pressing problems. We will work with you to establish rock-solid governance and operational practices that hold up to the scrutiny of the world’s best institutional investors. We will help you line up and credibly engage the right future investors for your business and trajectory. Let’s partner and make change happen.

Our planet is facing a multitude of urgent challenges; from climate change, dwindling natural resources and rapid urbanisation, to a growing demand for accessible healthcare. These pressing issues call for innovative and sustainable solutions that only scientific advancements can provide. Deep Science as an Asset Class.We invest in scientific breakthroughs that together advance human capability and create financial returns. We’re looking for: Entirely new technologies developed from fundamental research IP-rich innovations with competitive defensibility Solutions to real problems in Life Sciences, Advanced Materials, TechBio, Photonics and Quantum Hardware, Robotics and Automation, AgChem/Tech and DeepTech We offer portfolio exposure to deep science investments supported by a best-in-class due diligence process conducted by experienced entrepreneurs, operators, investors and scientists Investing with Empirical Ventures. ACCESS: leading pre-seed and seed rounds by leveraging our market-leading due diligence and domain expertise, opening doors to the best deals and co-investors SELECTION: our robust, highly selective process identifies cutting-edge scientific advances from the UK R&D landscape with the most compelling commercial opportunities SCALE: Our track record presents unparalleled opportunities to scale our portfolio companies and attract the best follow-on investors and talent POSITION: Our approach increases the probability of reaching Series A, a key inflection point for pre-seed and seed investors.

At Sagana Capital, we invest in pre-Series A – Series C rounds and funds with a significant social and/or environmental impact. We invest mainly on behalf of large, global families across topic areas including climatetech, energy transition, synthetic biology, sustainable fashion, food & agriculture, plastics & recycling, and healthcare & life sciences.

AI acceleration of scientific innovation and commercialization. Life Extension ventures invests in the two largest sectors in the world, People and Planet, where AI suddenly matters. Novel commercialization through marketplaces, networks, Web3, personalizations, payments, APIs, new go-to-markets and operations. Software, AI, and the power of the Internet will accelerate the adoption and monetization of science breakthroughs on human and planetary life. New infrastructure like SaaS, data platforms, OSs, LLMs, collaboration tools, storage, simulations, GenAI, visualization tools, security, workflow automation, Web3 and DAOs, or design tools to accelerate innovations. We target the infrastructure that accelerates the innovations. Software and AI are reinventing many industries bringing benefits to society and creating new category defining multibillion dollar companies; and now is the turn of climate, biology and health.

Unreasonable inventors are combining cutting edge scientific discoveries with the world's biggest challenges to build the next generation of global companies. These are the companies we create and invest in at Main Sequence. We have over $500m under management from lean-in LPs who help our portfolio to prosper. We are investing in the difficult to build companies others struggle to support. Our co-founder is Australia's $1.3b annual budget science agency - CSIRO We invest from seed to Series B, starting our journey as early as possible, driving advantage into our portfolio. Our Advantage Deep tech inventors need more. We have custom built Main Sequence to be ready to help you solve some of the world's greatest challenges with science. We are hands-on and have built a services offering to support founders alongside our capital. Our story Main Sequence was created by CSIRO to address the ‘valley of death’ between research and commercialisation. It solves the world’s greatest challenges by turning our scientific breakthroughs into the next century’s giants. Main Sequence’s origins within CSIRO reflect its commitment to amplifying connections between industry, research and infrastructure to accelerate deep technology development, and reinvesting economic returns from commercialisation back into science. CSIRO Innovation Funds 1 and 2 managed by Main Sequence, have invested in 39 companies since establishment in 2017. These companies have created over 1,200 jobs by working with partners in industry, CSIRO, and 22 Australian universities. The $240 million first CSIRO Innovation Fund , built on a cornerstone investment by government and CSIRO has completed its portfolio and invested in 27 companies since establishment in 2017. The second $300 million CSIRO Innovation Fund commenced investing mid-2021 and had already invested in 12 companies by the end of 2021. Following the Government’s announcement on 1 February 2022 of a reform agenda to accelerate commercialisation of research and collaboration with industry, including $150m support for CSIRO investment in future CSIRO Innovation Funds, Main Sequence welcomes the opportunity to continue to work closely with universities to commercialise Australian research and build Australian companies addressing global challenges. Each of our portfolio companies has some advantage delivered by either one of Australia's 43 universities or an industrial research organisation such as CSIRO. In some cases this exists before we invest, in others we facilitate it as part of the companies pathway to scale and impact.